Cargando…

Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study

OBJECTIVE: EMPOwER, a double-blind, randomised, phase 3 study, evaluated the efficacy and safety of erenumab in adults with episodic migraine from Asia, the Middle East, and Latin America. METHODS: Randomised patients (N = 900) received monthly subcutaneous injections of placebo, erenumab 70 mg, or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Shuu-Jiun, Roxas, Artemio A, Saravia, Bibiana, Kim, Byung-Kun, Chowdhury, Debashish, Riachi, Naji, Tai, Mei-Ling Sharon, Tanprawate, Surat, Ngoc, Tai Tran, Zhao, Yi Jing, Mikol, Daniel D, Pandhi, Shaloo, Wen, Shihua, Mondal, Subhayan, Tenenbaum, Nadia, Hours-Zesiger, Peggy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592099/ https://www.ncbi.nlm.nih.gov/pubmed/34171973 http://dx.doi.org/10.1177/03331024211024160

Ejemplares similares

Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study
por: Goadsby, Peter J., et al.
Publicado: (2021)

Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study
por: Ferrari, Michel Dominique, et al.
Publicado: (2022)

Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY study
por: Lanteri-Minet, Michel, et al.
Publicado: (2021)

Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial
por: Reuter, Uwe, et al.
Publicado: (2021)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study
por: Yu, Shengyuan, et al.
Publicado: (2022)

Efficacy and safety of erenumab in women with a history of menstrual migraine
por: Pavlovic, Jelena M., et al.
Publicado: (2020)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults
por: Sakai, Fumihiko, et al.
Publicado: (2019)

Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial
por: Tepper, Stewart J., et al.
Publicado: (2019)

One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study
por: Goadsby, Peter J., et al.
Publicado: (2020)

Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study
por: Lipton, Richard B., et al.
Publicado: (2019)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females
por: Xu, Yang, et al.
Publicado: (2019)

The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
por: Broessner, Gregor, et al.
Publicado: (2020)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021)

Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022)

Lichenoid drug eruption induced by erenumab
por: Musicante, Meryl, et al.
Publicado: (2022)

A Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina
por: Depre, Christophe, et al.
Publicado: (2018)

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study
por: Takeshima, Takao, et al.
Publicado: (2021)

Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies
por: Hirata, Koichi, et al.
Publicado: (2022)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial
por: Hirata, Koichi, et al.
Publicado: (2021)

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis
por: Ashina, Messoud, et al.
Publicado: (2022)

A longitudinal clinical and MRI evaluation of the treatment with erenumab
por: Coccia, Alberto, et al.
Publicado: (2020)

Predictors of response to erenumab after 12 months of treatment
por: Baraldi, Carlo, et al.
Publicado: (2021)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Myocardial infarction associated with erenumab: A case report
por: Perino, Justine, et al.
Publicado: (2022)

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine
por: Katsuki, Masahito, et al.
Publicado: (2023)

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
por: Ashina, Messoud, et al.
Publicado: (2019)

Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials
por: Tepper, Stewart J, et al.
Publicado: (2021)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
por: Manickam, Agaath Hedina, et al.
Publicado: (2021)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

Serum Uric Acid, Serum Uric Acid to Serum Creatinine Ratio and Serum Bilirubin in Patients With Parkinson’s Disease: A Case-Control Study
por: Songsomboon, Chayanon, et al.
Publicado: (2020)

Trigger of a migraine headache among Thai adolescents smartphone users: a time series study
por: Chongchitpaisan, Wanna, et al.
Publicado: (2021)

A prospective real-world analysis of erenumab in refractory chronic migraine
por: Lambru, Giorgio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dpv4932l7qujtc7cjuajf9f43j